Log In


Company Name : Bioventus

Thursday, March 16, 2017 3:40PM IST (10:10AM GMT)


Bioventus to Invest in New Clinical Research for EXOGEN®

Durham, N.C., United States

Bioventus, a global leader in orthobiologics,  announced it will commission an innovative series of real-world evidence, direct-to-patient studies to further validate the ability of its EXOGEN Ultrasound Bone Healing System to mitigate the risk of a fracture progressing to nonunion in the presence of known risk factors. FDA PMA approved in 1994, EXOGEN has provided treatment to more than 1 million patients worldwide for more than 20 years and has a long clinical history. The product uses safe, effective low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural healing process.1


This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170315005783/en/

EXOGEN Ultrasound Bone Healing System from Bioventus (Photo: Business Wire)

EXOGEN Ultrasound Bone Healing System from Bioventus (Photo: Business Wire)

Recent publications analyzing data from a large registry of almost 8,000 fractures treated with EXOGEN suggest that the device supports healing fractures in patients despite the presence of associated comorbidities or medication use.2,3,4 This new clinical research, known as the Bioventus Observational Non-interventional EXOGEN Studies (BONES), will build on this evidence and supplement the product’s broad body of clinical knowledge in a prospective population-based innovative clinical development program.


The BONES studies will compare the incidence of fracture nonunions in patients utilizing the EXOGEN device with patients from a national health insurance claims database who received standard of care alone. The studies will include bones representative of long and small bones of upper and lower extremities. The unique design was discussed with FDA during its development.


“BONES represents a significant investment in developing epidemiologically grounded rigorous clinical evidence to support use of EXOGEN in fractures at risk, and to underscore the product’s clinical utility in mitigating the risk of nonunions, a highly debilitating and costly condition,” said Alessandra Pavesio, Senior Vice President and Chief Science Officer, Bioventus. “It will build upon knowledge gained from extensive research conducted by Bioventus and recently published in JAMA Surgery, in over 700,000 fracture patients that has identified 40-plus factors which place a patient at an increased risk of progression to a nonunion.5


About Bioventus


Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN® Ultrasound Bone Healing System is the #1 prescribed bone healing system in the US and is the only FDA-approved bone healing device that uses safe, effective ultrasound to stimulate the body’s natural healing process. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.


For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.


Bioventus, the Bioventus logo, and EXOGEN are registered trademarks of Bioventus LLC.

  1. Azuma Y, Ito M, Harada Y, Takagi H, Ohta T, Jingushi S. Low-intensity pulsed ultrasound accelerates rat femoral fracture healing by acting on the various cellular reactions in the fracture callus. J Bone Miner Res. 2001; 16(4):671-680.
  2. Nolte P, Anderson R, Strauss E, Hu L, J Jones, RG Steen. 2016. Heal rate of metatarsal fractures: A propensity-matching study of low-intensity pulsed ultrasound (LIPUS) vs. surgical and other treatments. Injury. 2017 47(11):2584-2590.
  3. Zura R, G Della Rocca, S Mehta, A Harrison, C Brodie, J Jones, RG Steen. 2015. Treatment of chronic (> 1 year) fracture nonunion: Heal rate in a cohort of 767 patients treated with low-intensity pulsed ultrasound (LIPUS). Injury 46:2036-2041.
  4. Zura R, S Mehta, G Della Rocca, J Jones, RG Steen. 2015. A cohort study of 4,190 patients treated with low-intensity pulsed ultrasound (LIPUS): Findings in the elderly versus all patients. BMC Musculoskel. Dis. 16:45.
  5. Zura R, Xiong Z, Einhorn T, Watson JT, Ostrum RF, Prayson MJ, Della Rocca GJ, Mehta S, McKinley T, Wang Z, Steen RG. Epidemiology of Fracture Nonunion in 18 Human Bones, JAMA Surgery. 2016: e162775. doi:10.1001/jamasurg.2016.2775.

EXOGEN - Summary of Indications for Use in the US


*Summary of Indications for Use: The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions* excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization. There are no known contraindications for the EXOGEN device. Safety and effectiveness has not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling, at www.exogen.com or by contacting customer service at 1-800-836-4080. *A nonunion is considered to be established when the fracture site shows no visibly progressive signs of healing.



Click here for Media Contact Details
CONTACTS : BioventusThomas Hill, 919-474-6715thomas.hill@bioventusglobal.com

More News from Bioventus

14/09/2017 11:30PM

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN®

Bioventus, a global leader in orthobiologics, announced the first patients have been enrolled in its BONES (Bioventus Observational Non-interventional EXOGEN Studies) clinical development program. BONES includes three ...

18/01/2017 6:52PM

Bioventus Selects MEDSERVICE to Distribute DUROLANE® in Russia

Bioventus, a leader in orthobiologic solutions, announced it has selected MEDSERVICE to distribute DUROLANE® in Russia. DUROLANE is a single-injection joint-fluid based on a natural, safe and proven technology ...

15/11/2016 10:26AM

Bioventus Expands to Mexico with DUROLANE® for Knee Osteoarthritis Patients

Bioventus, a leader in orthobiologic solutions, has entered the patient care market in Mexico. This announcement reflects the company’s continued growth in international markets and its mission to partner with the ...

Similar News

23/01/2018 3:25PM

European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients

Takeda Pharmaceutical Company Limited (TSE: 4502) announced that the European Commission (EC) extended the current conditional marketing authorization of ADCETRIS® (brentuximab vedotin) and approved ADCETRIS ...

No Image

23/01/2018 2:50PM

Ferring enters into worldwide OmniAb® platform license agreement with Ligand

Ferring Pharmaceuticals announced today that it has entered into a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies for a ...